| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ADC Therapeutics SA (NYSE: ADCT)
ADCT Technical Analysis
2
| As on 24th Dec 2024 ADCT STOCK Price closed @ 2.03 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.45 & Strong Buy for SHORT-TERM with Stoploss of 1.28 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ADCTSTOCK Price
| Open | 1.98 | Change | Price | % |
| High | 2.05 | 1 Day | 0.04 | 2.01 |
| Low | 1.94 | 1 Week | 0.14 | 7.41 |
| Close | 2.03 | 1 Month | -0.95 | -31.88 |
| Volume | 303522 | 1 Year | 0.52 | 34.44 |
| 52 Week High 5.29 | 52 Week Low 0.47 | ||||
NYSE USA Most Active Stocks
| FSR | 0.02 | 0.00% |
| DDR | 15.44 | -4.46% |
| TWTR | 53.70 | 0.66% |
| SWN | 7.11 | -0.56% |
| BACA-U | 302.00 | 0.67% |
| RPAI | 13.15 | -3.17% |
| LTHM | 16.51 | -8.53% |
| SRC | 42.31 | -1.56% |
| AUY | 5.85 | -0.68% |
| PLTR | 83.16 | 5.31% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| ADCT Daily Charts |
ADCT Intraday Charts |
Whats New @ Bazaartrend |
ADCT Free Analysis |
|
|
ADCT Important Levels Intraday
| RESISTANCE | 2.24 |
| RESISTANCE | 2.17 |
| RESISTANCE | 2.13 |
| RESISTANCE | 2.09 |
| SUPPORT | 1.97 |
| SUPPORT | 1.93 |
| SUPPORT | 1.89 |
| SUPPORT | 1.82 |
ADCT Forecast December 2024
| 4th UP Forecast | 3.82 |
| 3rd UP Forecast | 3.25 |
| 2nd UP Forecast | 2.89 |
| 1st UP Forecast | 2.54 |
| 1st DOWN Forecast | 1.52 |
| 2nd DOWN Forecast | 1.17 |
| 3rd DOWN Forecast | 0.81 |
| 4th DOWN Forecast | 0.24 |
ADCT Weekly Forecast
| 4th UP Forecast | 2.76 |
| 3rd UP Forecast | 2.53 |
| 2nd UP Forecast | 2.38 |
| 1st UP Forecast | 2.24 |
| 1st DOWN Forecast | 1.82 |
| 2nd DOWN Forecast | 1.68 |
| 3rd DOWN Forecast | 1.53 |
| 4th DOWN Forecast | 1.30 |
ADCT Forecast2024
| 4th UP Forecast | 12.98 |
| 3rd UP Forecast | 9.47 |
| 2nd UP Forecast | 7.3 |
| 1st UP Forecast | 5.13 |
| 1st DOWN Forecast | -1.07 |
| 2nd DOWN Forecast | -3.24 |
| 3rd DOWN Forecast | -5.41 |
| 4th DOWN Forecast | -8.92 |
ADC Therapeutics SA ( NYSE USA Symbol : ADCT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ADCT Business Profile
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: Biopole, Epalinges, Switzerland, 1066
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service